Why the study?
Long-term recurrence after catheter ablation for AF remains challenging, and it is critical to understand how changing cardiovascular comorbidities captured by the CHA2DS2-VASc score affect post-ablation AF recurrence and MACCE.
Population
1,685 patients undergoing AF catheter ablation between January 2015 and December 2019
Comparison
Longitudinal (time-updated) CHA2DS2-VASc score changes
Design
Prospectively maintained single-center observational registry analysis
Follow-up
58.1 ± 17.1 months
Answers are grounded in this paper and cite their sources.
Does not support practice change in post-ablation care; leaves open value of dynamic CHA2DS2-VASc for recurrence prediction.
Introduction Catheter ablation is widely utilized for atrial fibrillation (AF) management, yet long-term recurrence remains challenging. It is critical to understand how cardiovascular comorbidities, as captured by the CHA 2 DS 2 -VASc score, affect AF recurrence and major adverse cardiovascular and cerebrovascular events (MACCE) after ablation. Methods This analysis used data from a prospectively maintained, single-center observational registry (ChiCTR-OCH-14004674) involving 1,685 patients who underwent AF catheter ablation between January 2015 and December 2019. The relationship between longitudinal (time-updated) CHA 2 DS 2 -VASc score changes and AF recurrence and MACCE was examined with time-to-event methods. Results Over the course of a 58.1 ± 17.1-month follow-up period, the CHA 2 DS 2 -VASc score rose from 1.84 ± 1.35 to 3.10 ± 1.44. AF recurrence was observed in 442 patients (26.2%). Patients with a changed CHA 2 DS 2 -VASc score demonstrated a higher incidence of AF recurrence (hazard ratio [HR] and 95% Confidence Interval [CI]: 1.552 (1.398–1.724), p < 0.001) and MACCE post-ablation (HR [95%CI]: 4.90 (3.21–7.50)). In a time-updated Cox model that used only information available before each event, this association persisted (AF recurrence HR [95% CI]: HR 4.98 (3.87–6.40) unadjusted; 5.48 (4.22–7.10) adjusted for age, sex and baseline CHA₂DS₂-VASc). Multivariable analyses identified an increasing CHA 2 DS 2 -VASc score, along with new-onset comorbidities such as diabetes, hypertension, and vascular disease, as significant predictors of AF recurrence. An increased CHA 2 DS 2 -VASc score was also markedly associated with the elevated MACCE risk. Notably, crossing an age threshold itself was not independently associated with recurrence; the prognostic signal was carried by incident non-age comorbidities rather than by aging per se. Discussion A changed CHA 2 DS 2 -VASc score serves as a dynamic and salient marker for AF recurrence and MACCE following AF ablation. Our findings highlight the importance of vigilant monitoring and management of cardiovascular risk factors in post-ablation patients.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: